Amylin pramlintide lowers glucose concentration in Type II diabetics on insulin, Phase II data suggest.
AMYLIN PRAMLINTIDE LOWERS GLUCOSE CONCENTRATION IN DIABETICS TAKING INSULIN, according to results of a one-month Phase II trial of 200 patients with Type II diabetes announced by the company Aug. 7. The Phase II trial evaluated pramlintide 30 mcg q.i.d., 60 mcg q.i.d. and 60 mcg t.i.d. "In all three dose groups, pramlintide administration produced a statistically significant lowering of fructosamine, a surrogate marker which reflects average glucose concentrations over a two-to-three week period," San Diego-based Amylin Pharmaceuticals reported.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth